# Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children

> **NCT00180908** · PHASE3 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 226 (—)

## Conditions studied

- Osteosarcoma
- Localised High Grade Osteosarcoma of the Limbs

## Interventions

- **DRUG:** Etoposide, Ifosfamide, Methotrexate
- **DRUG:** Doxorubicin, Methotrexate

## Key facts

- **NCT ID:** NCT00180908
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 226 (—)
- **Last updated:** 2005-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00180908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00180908, "Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00180908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*